Share-based Payment Arrangement, Expense of Cogent Biosciences, Inc. from 31 Mar 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cogent Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2017 to 30 Sep 2025.
  • Cogent Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $10,604,000, a 2.4% increase year-over-year.
  • Cogent Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $40,305,000, a 4.4% increase year-over-year.
  • Cogent Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $39,740,000, a 30% increase from 2023.
  • Cogent Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $30,621,000, a 67% increase from 2022.
  • Cogent Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $18,368,000, a 57% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cogent Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $40,305,000 $10,604,000 +$246,000 +2.4% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025 2025 Q3
Q2 2025 $40,059,000 $9,716,000 -$296,000 -3% 01 Apr 2025 30 Jun 2025 10-Q 05 Aug 2025 2025 Q2
Q1 2025 $40,355,000 $10,008,000 +$615,000 +6.5% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $39,740,000 $9,977,000 +$1,126,000 +13% 01 Oct 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
Q3 2024 $38,614,000 $10,358,000 +$1,601,000 +18% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025 2025 Q3
Q2 2024 $37,013,000 $10,012,000 +$2,849,000 +40% 01 Apr 2024 30 Jun 2024 10-Q 05 Aug 2025 2025 Q2
Q1 2024 $34,164,000 $9,393,000 +$3,543,000 +61% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $30,621,000 $8,851,000 +$3,814,000 +76% 01 Oct 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q3 2023 $26,807,000 $8,757,000 +$4,135,000 +89% 01 Jul 2023 30 Sep 2023 10-Q 12 Nov 2024 2024 Q3
Q2 2023 $22,672,000 $7,163,000 +$2,629,000 +58% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $20,043,000 $5,850,000 +$1,675,000 +40% 01 Jan 2023 31 Mar 2023 10-Q 07 May 2024 2024 Q1
Q4 2022 $18,368,000 $5,037,000 +$1,185,000 +31% 01 Oct 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
Q3 2022 $17,183,000 $4,622,000 +$1,159,000 +33% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $16,024,000 $4,534,000 +$1,944,000 +75% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $14,080,000 $4,175,000 +$2,394,000 +134% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $11,686,000 $3,852,000 +$2,986,000 +345% 01 Oct 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
Q3 2021 $8,700,000 $3,463,000 -$49,000 -1.4% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $8,749,000 $2,590,000 +$1,720,000 +198% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q2
Q1 2021 $7,029,000 $1,781,000 +$1,012,000 +132% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $6,017,000 $866,000 +$24,000 +2.8% 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q3 2020 $5,993,000 $3,512,000 +$2,724,000 +346% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $3,269,000 $870,000 -$15,000 -1.7% 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q1 2020 $3,284,000 $769,000 +$43,000 +5.9% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021 2021 Q1
Q4 2019 $3,241,000 $842,000 -$538,521 -39% 01 Oct 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
Q3 2019 $3,779,521 $788,000 -$72,000 -8.4% 01 Jul 2019 30 Sep 2019 10-Q 09 Nov 2020 2020 Q3
Q2 2019 $3,851,521 $885,000 +$38,000 +4.5% 01 Apr 2019 30 Jun 2019 10-Q 11 Aug 2020 2020 Q2
Q1 2019 $3,813,521 $726,000 +$725,521 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q4 2018 $3,088,000 $1,380,521 +$920,521 +200% 01 Oct 2018 31 Dec 2018 10-K 26 Mar 2020 2019 FY
Q3 2018 $2,167,479 $860,000 +$561,000 +188% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $1,606,479 $847,000 +$565,000 +200% 01 Apr 2018 30 Jun 2018 10-Q 12 Aug 2019 2019 Q2
Q1 2018 $1,041,479 $479* -$299,521 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019 2019 Q1
Q4 2017 $1,341,000 $460,000 01 Oct 2017 31 Dec 2017 10-K 28 Mar 2019 2018 FY
Q3 2017 $299,000 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018 2018 Q3
Q2 2017 $282,000 01 Apr 2017 30 Jun 2017 10-Q 13 Aug 2018 2018 Q2
Q1 2017 $300,000 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1

Cogent Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $39,740,000 +$9,119,000 +30% 01 Jan 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
2023 $30,621,000 +$12,253,000 +67% 01 Jan 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
2022 $18,368,000 +$6,682,000 +57% 01 Jan 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
2021 $11,686,000 +$5,669,000 +94% 01 Jan 2021 31 Dec 2021 10-K 26 Feb 2024 2023 FY
2020 $6,017,000 +$2,776,000 +86% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2022 2021 FY
2019 $3,241,000 +$153,000 +5% 01 Jan 2019 31 Dec 2019 10-K 16 Mar 2021 2020 FY
2018 $3,088,000 +$1,747,000 +130% 01 Jan 2018 31 Dec 2018 10-K 26 Mar 2020 2019 FY
2017 $1,341,000 01 Jan 2017 31 Dec 2017 10-K 28 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.